OTCMKTS:JBPHF Jacobio Pharmaceuticals Group (JBPHF) Stock Price, News & Analysis $0.64 0.00 (0.00%) As of 08/6/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Jacobio Pharmaceuticals Group Stock (OTCMKTS:JBPHF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get JBPHF alerts:Sign Up Key Stats Today's Range$0.64▼$0.6450-Day Range$0.60▼$0.8752-Week Range$0.60▼$0.64VolumeN/AAverage Volume300 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Jacobio Pharmaceuticals Group Co., Ltd. is a clinical‐stage biopharmaceutical company headquartered in Tianjin, China, specializing in the discovery and development of small‐molecule therapeutics for oncology. The company’s research platform is built around targeted kinase inhibitors and epigenetic modulators aimed at addressing acute leukemias and select solid tumors with high unmet medical need. Jacobio’s pipeline comprises multiple preclinical and clinical‐stage programs focused on genetically defined cancers, including agents designed to inhibit mutant FLT3, menin‐MLL interactions and other oncogenic drivers. Through its internal R&D capabilities, the company advances its lead candidates from target validation through Phase I/II studies, seeking to establish proof-of-concept in both monotherapy and combination regimens. Since its founding in 2007, Jacobio has expanded its footprint across mainland China, with research centers in Tianjin and collaborative networks involving academic institutions and contract research organizations. The company maintains in-house manufacturing capacity for early-stage compounds and pursues strategic partnerships to support late-stage development and potential global commercialization.AI Generated. May Contain Errors. Read More Receive JBPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jacobio Pharmaceuticals Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBPHF Stock News HeadlinesJacobio Starts Phase IIa Trial of First BET Inhibitor for Rheumatoid Arthritis in ChinaJuly 26, 2026 | tipranks.comJacobio Starts Phase Ib/III Trial of Pan-KRAS Inhibitor for KRAS-Mutant Pancreatic Cancer in ChinaJuly 19, 2026 | tipranks.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 7 at 1:00 AM | Investors Alley (Ad)Jacobio Pharmaceuticals Launches HK$100 Million Share Buyback PlanJune 7, 2026 | tipranks.comJacobio Shareholders Back All Resolutions at 2026 AGM, Renewing Capital MandatesJune 5, 2026 | tipranks.comJacobio Secures US$100 Million Upfront From AstraZeneca for Pan-KRAS Cancer DrugMarch 29, 2026 | tipranks.comJacobio Pharma: Differentiated Pan-KRAS Profile, Multiple Clinical Catalysts, and Solid Balance Sheet Underscore Buy RatingMarch 12, 2026 | tipranks.comJacobio’s JAB-2485 Trial Progress: Early Cancer Data in Focus for HK:1167 InvestorsJanuary 9, 2026 | tipranks.comSee More Headlines JBPHF Stock Analysis - Frequently Asked Questions How have JBPHF shares performed this year? Jacobio Pharmaceuticals Group's stock was trading at $0.9479 at the beginning of 2026. Since then, JBPHF stock has decreased by 32.5% and is now trading at $0.6403. How do I buy shares of Jacobio Pharmaceuticals Group? Shares of JBPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:JBPHF CIKN/A Webwww.jacobiopharma.com Phone86-10-5631-5466FaxN/AEmployees301Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:JBPHF) was last updated on 8/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jacobio Pharmaceuticals Group Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jacobio Pharmaceuticals Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.